ImmuneOnco received ‘Hi-Tech Enterprise Certificate’
On March 05, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter refer to as ImmuneOnco) announced receiving ‘Hi-Tech Enterprise Certificate’. This certificate is jointly issued by Shanghai Municipal Science and Technology Commission, Shanghai Municipal Finance Bureau and Shanghai Taxation Bureau of State Administration of Taxation.
The recognition of a ‘ Hi-tech enterprise’ refers to an enterprise that continues to carry out R&D and transformation of technology to get rights reserved of intellectual property of the enterprise, and carries out activities of production and operation within the high-tech fields supported by the state, consistent with the national aim of cultivating and developing new technologies and new types of business, and promoting economic upgrading and advancement. The acquisition of ‘Hi-Tech Enterprise Certificate’ is a full affirmation to scientific and technological innovation of the company, key independent intellectual property rights, ability of transforming science to technological achievements, organization and management level of R&D and company growth.
According to official regulations, the enterprises recognized as ‘high-tech enterprise’ will not only take advantage of tax policy of paying corporate income tax at the rate of 15%, but also have the priority to hire and the city settlement in Shanghai, and the opportunity of application of various kinds of government supported funds and other preferential policies, which will provide an important certificate for ImmuneOnco’s qualification in the industry.
"I am very glad that ImmuneOnco is recognized by authorities. The honor verifies powerful R&D and innovation ability of our company, reveals overall strength of our company, enhances the enterprise brand image and market value. It makes our company more attractive to more science talents and strongly supports to develop global market’. Dr. Tian Wenzhi, the founder of ImmuneOnco, also said: ‘ ImmuneOnco will take this opportunity to increase investment in research and development, to accelerate the pace of technological innovation, to build a high-quality medical personnel team, and to inject new vitality for the high-quality development of the enterprise constantly’.
ImmuneOnco Biopharmaceutical Technology (Shanghai) Co., Ltd. was founded in June 2015 and registered in Shanghai Zhangjiang Hi-Tech Park. The company focuses on the development of next-generation immunotherapy products for cancer treatment, including
bi-specific antibodies, novel recombinant proteins, and TANKTM cell therapies. The company deeply ploughs the CD47 target development to enrich pipelines. At present, IMM01 and IMM0306 are in phase I clinical development for refractory or relapsed liquid tumors to bring new hope to those cancer patients.
For further cooperation, please contact
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573